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Abstract Purpose: Selective
digestive microbial decontamination
(SDD) is hypothesized to beneﬁt
patients in intensive care (ICU) by
suppressing Gram-negative potential
pathogens from the colon without
affecting the anaerobic intestinal
microbiota. The purpose of this study
was to provide more insight to the
effects of digestive tract and oropha-
ryngeal decontamination on the
intestinal microbiota by means of a
prospective clinical trial in which
faecal samples were collected from
ICU patients for intestinal microbiota
analysis. Methods: The faecal sam-
ples were collected from ICU patients
enrolled in a multicentre trial to study
the outcome of SDD and selective
oral decontamination (SOD) in
comparison with standard care (SC).
Fluorescent in situ hybridization
(FISH) was used to analyze the faecal
microbiota. The numbers of bacteria
from different bacterial groups were
compared between the three regi-
mens. Results: The total counts of
bacteria per gram faeces did not differ
between regimens. The F. prausnitzii
group of bacteria, representing an
important group among intestinal
microbiota, was signiﬁcantly reduced
in the SDD regimen compared to the
SC and SOD. The Enterobacteria-
ceae were signiﬁcantly suppressed
during SDD compared to both SOD
and SC; enterococci increased in
SDD compared to both other regi-
mens. Conclusions: The
composition of the intestinal micro-
biota is importantly affected by SDD.
The F. prausnitzii group was signiﬁ-
cantly suppressed during SDD. This
group of microbiota is a predominant
producer of butyrate, the main energy
source for colonocytes. Reduction of
this microbiota is an important trade-
off while reducing gram-negative
bacteria by SDD.
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Introduction
Selective (microbial) decontamination of the digestive
tract (SDD), developed using immuno-compromised
animal models [1, 2], was ﬁrst clinically tested in severely
immuno-compromised hemato-oncological patients and
later applied to patients admitted to intensive care units
(ICU) [3]. The concept of SDD is to selectively suppress
potential pathogens, mostly Gram-negative bacteria,
without disturbing the anaerobic intestinal microbiota.
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prophylactic systemic antimicrobial treatment (3rd gen-
eration cephalosporins) during the ﬁrst four days to
eradicate potential pathogens. In order to protect the
anaerobic microbiota, the use of antibiotics with anti-
anaerobic activity was discouraged.
Earlier studies were ﬂawed by design [3] or lacked
statistical power to detect a survival advantage. Meta-
analyses showed a signiﬁcant survival advantage [4, 5]
one did not [6]. Also single centre randomized trials
evaluating SDD showed reduction in mortality [7, 8].
A consistent ﬁnding across studies evaluating SDD in
the ICU has been a reduction of the number of episodes of
nosocomial infections—especially, of respiratory tract.
As the prevention of ventilator-associated pneumonia
(VAP) might play a dominant role in the mortality
reduction of SDD, the oropharyngeal component of SDD,
referred to as Selective Oropharyngeal Decontamination
(SOD), has also been analysed in clinical trials [9].
Although a signiﬁcant reduction in VAP was shown,
historically no overall reduction in mortality by SOD [10]
or non-selective oral decontamination [11] was observed.
A large multi-centre clinical trial of SOD and SDD
was recently reported. In this trial both SDD and SOD
showed a similar survival beneﬁt compared to standard
care (SC) [12]. As an adjunct to this study we investigated
the impact of SOD and SDD regimes on the intestinal
microbiota compared to SC.
The intestinal microbiota is a complex ecosystem which
comprises more than 10
11 bacteria per gram of faeces and
more than 400 different species [13]. Some of the intestinal
microbiota are beneﬁcial and ways to promote their growth
have been investigated [14]. With the use of SDD, the
intestinalmicrobiotaisbelievedtoprotectthehumanhostby
preventing increased colonisation with potential pathogens
[15],mostlyanaerobicbacteriathataredifﬁculttoisolateand
identifybyclassicalculturetechniques.Quantiﬁcationofthe
anaerobicmicrobiotabasedonculturemethodsisunreliable:
selective media introduce bias; and many genera cannot be
cultured in vitro. Molecular methods, such as ﬂuorescent in
situ hybridisation (FISH), yield absolute numbers of micro-
organisms[16,17]insteadofcolony-formingunits,whichis
the quantitative read-out of culture.
In the present study we evaluate, for the ﬁrst time with
molecular methods, the impact of SDD and SOD on the
intestinal microbiota compared to SC in subjects admitted
to ICU. We tested the hypothesis that SDD (or SOD) may
execute its claimed beneﬁcial effects by leaving the
anaerobic intestinal microbiota unaffected.
Patients and methods
All patients consecutively admitted to the Medical ICU
in our hospital, and that were evaluated within the
framework of the Dutch multi-centre SDD-SOD study
[12], were eligible. In this SDD-SOD study, participating
centres followed three different regimens of treatment in
their ICUs in a non-blinded random sequence:
1. SC: no prophylactic antimicrobials, no restrictions in
the antibiotics used
2. SOD: prophylactic topical oropharyngeal antimicrobi-
als, no restrictions in the antibiotics used.
3. SDD: prophylactic topical oropharyngeal and gastro-
intestinal antimicrobials, with the addition of intrave-
nous cefotaxime during the ﬁrst four days. Selective
use of antimicrobials was encouraged to avoid inter-
ference with the intestinal microbiota, in accordance
with the concept of colonisation resistance.
The sequence of these courses allocated to our hos-
pital was SC–SOD–SDD. For details of the trial and the
antibiotic regimens used, we refer to the original article
[12]. All included patients were scored for their severity
of disease with the APACHE II classiﬁcation system
[18]. Other parameters that were recorded are demo-
graphics (age, gender etc.), concomitant diseases and the
use of all antimicrobial products including the antimi-
crobials used for the prophylactic protocols (SOD and
SDD).
During all three consecutive trial periods, faecal
samples were collected from the patients that produced
faeces spontaneously or with the use of laxatives as on
clinical indication alone. For every patient, only the ﬁrst
sample faecal that was passed after at least three days of
period-speciﬁc treatment by patients on mechanical ven-
tilation was used in order to avoid skewing of data (see
Fig. 1).
For the multi-centre SOD-SDD study, a waiver from
informed consent was provided by local and National
Ethics Review Boards, as not patients but rather different
standards of treatment protocols were compared in a
randomized fashion. Samples and data were analyzed
anonymously.
Materials and methods
All fresh faecal samples were stored in a refrigerator and
processed for analysis within 24 h after collection. The
processing procedure was as follows: after homogeniza-
tion, from each faecal sample 1.0 g (wet weight) was
taken and diluted in PBS (8 g/L NaCl, 0.2 g/L KCl,
1.44 g/L Na2HPO4 2H2O, 0.24 g/L KH2PO4, pH 7.4) 1:4
or 1:9 depending on faecal consistency. The faecal con-
sistency was scaled on the Bristol Stool chart, where
consistencies of stool type 1–6 were diluted 1:9, type 7
was diluted 1:4. These dilutions were processed for
storage as described previously [19].
1395For quantiﬁcation of the bacteria in faecal samples,
multiple slides with 1 cm
2 wells were prepared for cell
counting and hybridized as described previously [19].
Hybridization was performed using the 16S rRNA-tar-
geted probes listed in table 1.
The probes were manufactured by Eurogentec
(Seraing, Belgium). Together these probes detect
approximately 90% of the expected hybridisable total
amount of bacteria (Eub338) [17]. Additional to the probe
set for detection of the normal intestinal microbiota, three
probes were used to enumerate groups of potential
pathogens. These are the EC1531 [20] probe for the
Enterobacteriaceae and the Enﬂ84 and Enfm93 [21]t o
detect enterococci.
ICU admissions during study period:  
n = 1132
SC
(standard care):                                 (oral treatment):                        (oral & s stemic treatment):
n=140
SOD
n=111
n=98
no mechanical 
ventilation, or < 3 
days period specific
treatment: n=21
no mechanical 
ventilation, or < 3 
days period specific 
treatment: n=18
SDD
n=86
n=59
no mechanical 
ventilation, or < 3 
days period specific 
treatment: n=10
no faeces: 
days period specific
treatment: n=21 treatment: n=10
: s e c e a f o n : s e c e a f o n
n=74
￿ Admissions <2d: n=633 
￿ Admissions >2d, non- eligible:   
n=102 
Eligible for study 
enrollment: 
n=397 
￿     Missed inclusions: n=43 
￿     Loss between periods: n=17 
Study population: 
n=337
included in 
the study: 
21
included in 
the study: 
19
included in 
the study: 
17
y
Fig. 1 Flow chart of patient
selection
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using an automated microscope system [22]. The detec-
tion limit used with this method was 10
6 cells/g of faeces.
After analysis of the FISH results, minimal inhibitory
concentrations (MIC) to the SDD/SOD antibiotics of a
type strain of F. prausnitzii were performed. The A2-165
strain of F. prausnitzii was cultured in an anaerobic
cabinet on YCFA agar-plates. YCFA medium consisted
of (per 100 ml): 1 g casitone, 0.25 g yeast extract, 0.4 g
NaHCO3, 0.1 g cysteine, 0.045 g K2HPO4, 0.045 g
KH2PO4, 0.09 g NaCl, 0.009 g MgSO4.7H2O, 0.009 g
CaCl2, 0.1 mg resazurin, 1 mg haemin, 1 lg biotin, 1 lg
cobalamin, 3 lg p-aminobenzoic acid, 5 lg folic acid and
15 lg pyridoxamine. Final concentrations of short-chain
fatty acids (SCFA) in the medium were 33 mM acetate,
9 mM propionate and 1 mM each of isobutyrate, isoval-
erate and valerate.
The MIC tests were performed using E-test -strips
containing tobramycin, colistin and cefotaxime, according
to the instructions of the manufacturer (AB BIODISK,
Solna, Sweden).
Statistics
The results were compared statistically between the three
patient groups using SPSS
 16 statistical analysis soft-
ware. For the continuous variables age and APACHE-
scores, ANOVA analyses were performed, for nominal
variables such as antibiotics use, a Chi-square cross tab-
ulation with a Fisher’s Exact test was used (see Table 2
for details).
The analysis of the numbers of bacteria was done with
an ANOVA analysis after log-transformation to obtain a
normal distribution. The normal distribution was checked
with the Kolmogorov-Smirnoff test and by evaluation of
P–P plots.
The numbers of enterococci however were still not
normally distributed after log-transformation, therefore
for these bacterial groups non-parametric tests (MWU)
were performed.
Results
Patients: Figure 1 shows the ﬂowchart of the patient
sample selection. Faecal samples were collected for
analysis from a total of 21 patients in the SC regimen, 19
patients in the SOD regimen and 17 patients in the SDD
regimen.
The age distribution of patients did not differ signiﬁ-
cantly between the three study episodes; in the SC group,
the mean age was 59.8, in the SOD group 63.7 and in the
SDD group 56.7.
APACHE-II scores were also similar between groups:
14.3, 15.4 and 16.2 for the SC, SOD and SDD groups,
respectively. The APACHE predicted (adjusted) death
rate was higher in both the SOD and SDD regimen
groups. These differences were not statistically signiﬁ-
cant. Furthermore enteral tube feeding and gastric
retention did not differ statistically signiﬁcantly between
the three regimen groups, see table 2 for details.
Except for the use of cephalosporins (which are a part
of the SDD regimen) the use of antibiotics did not differ
signiﬁcantly between the regimens. Because no statistical
difference in the characteristics of the population was
found, no further multivariate analysis was performed.
No signiﬁcantimpact of SDD was observed on the total
number of bacteria of the colonic microbiota (Table 3).
There is, however, a signiﬁcant difference in the compo-
sition of the microbiota of the different regimens. Some
differences are seen in the bacterial groups between the
analysed regimens, but the numbers of the F. prausnitzii
group in the SDD-regimen are signiﬁcantly lower com-
pared to both Standard Care and the SOD regimen. The
Eubacterium rectale group shows lower numbers of bac-
teria in the SDD regimen compared to the SC regimen. A
Table 1 Probes used for the detection of the intestinal microbiota
Target Probe Sequence
Total bacteria EUB338 50GCTGCCTCCCGTAGGAGT
Bacteroides/Prevotella Bac303 50CCAATGTGGGGGACCTT
E. rectale/Blautia coccoides Erec482 50GCTTCTTAGTCA(G/A)GTACCG
F. prausnitzii-group Fprau645 50CCTCTGCACTACTCAAGAAAAAC
Atopobium-group Ato291 50GGTCGGTCTCTCAACCC
Biﬁdobacteria Bif164 50CATCCGGCATTACCACCC
Ruminococci Rbro730 50TAAAGCCCAGYAGGCCGC
Rﬂa729 50AAAGCCCAGTAAGCCGCC
Roseburia cluster Rint623 50TTCCAATGCAGTACCGGG
Rint helper 50GTTGAGCCCCGGGCTTT
Enterobacteriaceae EC1531 50CACCGTAGTGCCTCGTCATCA
Enterococcus faecalis Enﬂ84 50CCTCTTTCCAATTGAGTGCA
Enterococcus faecium-group Enfm93 50GCCACTCCTCTTTTTCCGG
References to the probes can be found in the supplementary material
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group—also shows lower numbers in the SDD regimen.
SDD had a signiﬁcant impact on potential Gram-
negative pathogen counts in the faecal microbiota to
which it is targeted. Enterobacteriaceae in the SDD
regimen were signiﬁcantly reduced in numbers compared
to both the SC-regimen and the SOD-regimen.
The gram-positive potential pathogens such as the
enterococci increased signiﬁcantly with the use of SDD,
in comparison with both other regimens (Table 4). A
signiﬁcant rise in Enterococcus faecalis was also seen in
the SOD regimen compared to the SC regimen. However,
the numbers of E. faecalis in the SOD regimen were still
signiﬁcantly lower than when compared to the numbers of
E. faecalis in the SDD regimen.
The MIC values of F. prausnitzii A2-165 for the SDD/
SOD antibiotics were 4 lg/ml for tobramycin,[32 lg/ml
for cefotaxime and[256 lg/ml for colistin.
Discussion
The major ﬁnding in this study was that the composition
of the intestinal microbiota, as evidenced by stool anal-
ysis, was affected by the use of SDD: the F. prausnitzii
group was signiﬁcantly reduced in numbers in stools of
subjects receiving SDD compared to subjects in both
other regimens. This ﬁnding contrasts with the hypothesis
of SDD that anaerobic microbiota would remain unaf-
fected [15].
The group of bacteria detected with the Fprau-probe
is one of the predominant bacterial groups in healthy
volunteers, representing 10–15% of the intestinal mic-
robiota on average [17, 23]. The F. prausnitzii group
therefore plays an important role in maintaining the
colonization resistance, normally protecting the human
host from infections. F. prausnitzii has also been found
to have anti-inﬂammatory effects which may play a
Table 2 Characteristics of the patient population
Variable SC SOD SDD
n 21 19 17
ANOVA
Age (years)
Mean 59.8 63.7 56.7
95% CI 53.3–66.2 55.2–72.3 50.0–63.5
APACHE
Mean 14.3 15.4 16.2
95% CI 11.7–16.9 12.2–18.7 11.4–21.0
APACHE predicted death rate
Mean 16.0 22.6 25.5
95% CI 10.8–21.3 14.1–31.0 11.7–39.1
Enteral feeding (ml/day)
Mean 1807 1953 1912
95% CI 1701–1913 1779–2126 1802–2021
Gastric retention (ml/day)
Mean 355 120 147
95%CI 120–590 16–224 35–259
Length of stay in the ICU before sampling (days)
Mean 8.2 8.5 11.1
95% CI: 6.8–9.7 5.6–11.4 7.4–14.7
Median 8 5 5
SC (%) SOD (%) SDD (%) SCvsSOD (p)
a SCvsSDD (p)
a SODvsSDD (p)
a
Fisher’s exact-tests
In-hospital mortality 38.1 26.3 47.1 0.51 0.74 0.30
Admission type
Surgical 19.0 15.8 5.9 1.00 0.36 0.61
Medical 81.0 84.2 94.1
Antibiotics before ICU admission 28.6 36.4 29.4 0.74 1.00 0.73
Systemic antibiotics in the ICU
Beta-lactam 14.3 15.8 29.4 1.00 0.68 0.68
Beta-lactam ? inhibitor 71.4 42.1 41.2 0.11 0.10 1.00
Cephalosporin 14.3 31.6 88.2 0.27 0.00 0.00
Quinolones 33.3 42.1 23.5 0.75 0.72 0.30
Aminoglycosides 0.0 5.3 0.0 0.48 1.00
Vancomycin 9.5 15.8 11.8 0.65 1.00 1.00
Clindamycin 4.8 0.0 0.0 1.00 1.00
Metronidazole 0.0 5.3 5.9 0.48 0.45 1.00
Cotrimoxazole 9.5 5.3 0.0 1.00 0.49 1.00
a Fisher’s exact-test
1398dominant role in the development of Crohn’s disease
[24].
Furthermore, the F. prausnitzii group is considered to
provide special health beneﬁt for the human host because
of its main fermentation product, butyrate [23, 25].
Butyrate is a short chain fatty acid that is the primary
source of energy for the colonocytes [26]. In addition,
butyrate promotes the growth of colonocytes, preventing
mucosal atrophy. It also appears to lower the risk of
malignant transformation of colonocytes in animal mod-
els [27]. The optimal concentration of butyrate is not
known in vivo, but in vitro cell cultures show a growth
arrest at concentrations below 10 mM [26]. In healthy
volunteers, butyrate concentrations were also reduced
during tube feeding [28], and in a blinded re-analysis of
these faecal samples, the reduction of F. prausnitzii
showed strong correlation with the reduction of butyrate
measured in these faecal samples (manuscript submitted).
The F. prausnitzii-group of bacteria is difﬁcult to
culture in vitro and therefore could not be detected when
SDD was ﬁrst developed. Only culture-based methods
were used to asses whether the intestinal microbiota
remained intact in the early days of SDD. Therefore, this
unintended effect could not have been foreseen when the
regimen was ﬁrst used. The MIC analysis of the SDD/
SOD antibiotics shows that F. prausnitzii is susceptible
only to tobramycin at 4 lg/ml. This concentration of
tobramycin is easily reached with the intestinal decon-
tamination regimen of SDD. The reduction of F. pra-
usnitzii is therefore most likely caused by the intesti-
nal administration of tobramycin in the SDD-regimen
group.
We show that the loss of F. prausnitzii is not com-
pensated for by an increase of other important butyrate-
producing bacteria. Roseburia spp., another important
group of butyrate producing bacteria, are also present in
signiﬁcantly lower numbers during the SDD regimen
compared to the SC regimen. Similar to F. prausnitzii,
reductions in numbers of bacteria from the Roseburia spp.
correlate to a reduction in the amount of butyrate which is
produced [29]. Therefore, we postulate that butyrate
production may be impaired in SDD patients due to the
loss of these predominant butyrate-producing bacterial
groups.
Clear evidence that the SDD regimen was given
according to protocol is the fact that a signiﬁcant reduc-
tion in the Enterobacteriaceae was found in the SDD
regimen compared to both other regimens. The numbers
of Enterobacteriaceae in the SC and SOD regimens were
markedly higher than in healthy individuals [17].
Table 3 Numbers and statistical analysis of the main intestinal microbiota groups
Variable Regimen:
SC (21
a) SOD (19
a) SDD (17
a)
Mean 95% CI Mean 95% CI Mean 95% CI
Probe
Total bacteria 3.7 9 10
9 2.2 9 10
9–6.2 9 10
9 1.6 9 10
9 7.8 9 10
8–3.4 9 10
9 1.9 9 10
9 8.7 9 10
8–4.3 9 10
9
Bacteroides 6.5 9 10
8 3.5 9 10
8–1.2 9 10
9 3.6 9 10
8 1.4 9 10
8–9.5 9 10
8 4.2 9 10
8 2.1 9 10
8–8.1 9 10
8
E. rectale
b 5.1 9 10
8 3.0 9 10
8–8.5 9 10
8 1.4 9 10
8 5.4 9 10
7–3.4 9 10
8 6.2 9 10
7 2.6 9 10
7–1.4 9 10
8
R. intestinalis
b 6.8 9 10
7 3.7 9 10
7–1.3 9 10
8 1.8 9 10
7 7.0 9 10
6–4.8 9 10
7 1.1 9 10
7 4.9 9 10
6–2.7 9 10
7
F. prausnitzii
c 5.5 9 10
7 2.3 9 10
7–1.3 9 10
8 4.0 9 10
7 1.6 9 10
7–9.9 9 10
7 2.9 9 10
6 1.4 9 10
6–6.0 9 10
6
Atopobium 1.3 9 10
8 6.6 9 10
7–2.3 9 10
8 3.5 9 10
7 1.3 9 10
7–9.2 9 10
7 4.2 9 10
7 1.4 9 10
7–1.2 9 10
8
Biﬁdobacteria 4.4 9 10
7 1.6 9 10
7–1.2 9 10
8 1.6 9 10
7 5.4 9 10
6–4.6 9 10
7 5.8 9 10
7 1.8 9 10
7–1.8 9 10
8
Ruminococci 2.0 9 10
8 1.3 9 10
8–3.3 9 10
8 8.6 9 10
7 3.8 9 10
7–2.0 9 10
8 7.8 9 10
7 3.1 9 10
7–1.7 9 10
8
Enterobacteriaceae
c 7.2 9 10
7 3.6 9 10
7–1.4 9 10
8 4.8 9 10
7 1.7 9 10
7–1.4 9 10
8 4.1 9 10
6 2.0 9 10
6–8.3 9 10
6
ANOVA test was used for statistical analysis
a Number of study subjects
b Indicates a signiﬁcant difference between the SDD and SC reg-
imens only
c Indicates a signiﬁcant difference between SDD and both SC and
SOD regimens
Table 4 Numbers and statistical analysis of enterococci per gram faeces
SC (n = 21) SOD (n = 19) SDD (n = 17) SC vs. SOD
a SC vs. SDD
a SOD vs. SDD
a
E. faecalis 2.6 9 10
6 7.6 9 10
6 6.9 9 10
7 0.002 0.000 0.000
E. faecium 6.3 9 10
6 9.8 9 10
6 5.4 9 10
7 0.142 0.000 0.000
a Mann–Whitney U-tests, p values
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SDD regimen [8, 12, 30]. Although cefotaxime has been
shown to have a moderate suppressive effect on Entero-
bacteriaceae [31, 32], we have reasons to believe that the
effect of cefotaxime is negligible compared to the effect
of the large amounts of non-absorbable antibiotics tar-
geted speciﬁcally to Enterobacteriaceae.
Cefotaxime elimination is almost entirely by renal
excretion; only 5% of elimination is by biliary excretion,
and the amount of cefotaxime reaching the colon is
exceedingly low compared to the amounts of non-
resorbable tobramycin and colistin, both active against
Enterobacteriaceae. Early studies haven shown that cef-
otaxime is almost entirely inactivated by faecal enzymes
[33]. This is not the case with colistin and tobramycin,
which makes it most likely that the effect seen is caused
by these antibiotics instead. Furthermore the earlier
studies of the effects of cefotaxime on the intestinal
microbiota are based upon culturing methods with
selective plates. Especially when antibiotics are used,
these methods can lead to underestimation of the actual
numbers of bacteria.
The second important ﬁnding is that SOD left the
faecal microbiota relatively unaffected compared to stools
from patients enrolled during the SC period of the study.
As shown in the multi-center clinical trial [12], there is no
signiﬁcant difference in mortality between SDD and
SOD, despite the fact that colonisation and infections with
Enterobacteriaceae are signiﬁcantly reduced in SDD
compared to SOD. This reduction of Enterobacteriaceae
is conﬁrmed in our study. We speculate that the lack of
further mortality reduction is partly explained by the
negative effect of SDD on beneﬁcial bacteria of the
colonic microbiota. How the loss of these beneﬁcial
bacteria, which provide an important source of nutrition
for colonocytes, translates into clinically signiﬁcant
effects in general, and in critically ill patients in partic-
ular, is presently unknown. The role of microbiota and the
production and uptake of butyrate in particular to main-
tain colonic integrity in a range of conditions, including
critical care settings with sepsis, should perhaps be
studied in animal models.
The Biﬁdobacteria showed a mild increase in the SDD
regimen that did not reach statistical signiﬁcance. These
Gram-positive bacteria are not susceptible to the antibi-
otics used in SDD.
A third consideration with the use of SDD is the
increase of enterococci in the faeces [34]. Although the
numbers of E. faecalis are also signiﬁcantly higher in the
SOD regimen compared to the SC regimen, the numbers
of enterococci in the SDD regimen are an order of mag-
nitude higher than in both other regimens. It is historically
known that enterococci tend to increase in numbers under
similar use of topical antibiotics [35], as these Gram-
positive bacteria are naturally resistant to the SDD-anti-
biotics. Also, Gram-negative intestinal bacteria induce an
antimicrobial peptide, Reg3g, at the luminal surface of
intestinal cells by stimulating TLR4 [36], with growth
limiting effects on enterococci. Elimination of Gram
negative bacteria resulted in a decrease of Reg3g with
subsequent increase and translocation of enterococci in a
mouse model [36].
The enterococci were considered to be harmless when
SDD was ﬁrst introduced in the ICU and none of the
included patients had bloodstream infections with
enterococci. However, we are aware that enterococci
cause serious nosocomial infections, spread easily, and
acquire increased antibiotic resistance [37, 38]. Entero-
cocci are the third leading cause of endocarditis, and
nosocomial acquisition is associated with a poor
prognosis [39, 40]. Furthermore, antibiotic resistance
gene-transfer has been demonstrated in vivo between
enterococci and other bacterial species [41].
Limitations to the study are the limited numbers of
patients and samples. Also, by design of the study, no
baseline samples could be obtained nor could the timing
of the sampling be standardized, as all samples were
produced spontaneously. Based upon the data provided in
table 2 we believe this has not caused a major source of
bias.
Conclusion
We show that the total numbers of bacteria of the faecal
microbiota in patients in the ICU are not signiﬁcantly
inﬂuenced by SDD. Enterobacteriaceae dropped signiﬁ-
cantly in numbers in the SDD regimen compared to SC
and SOD regimens, as expected.
SDD does have a signiﬁcant impact on the com-
position of the anaerobic intestinal microbiota; the
number of F. prausnitzii-group of bacteria is signiﬁ-
cantly reduced during the SDD regimen compared to
both SC and SOD regimens. The bacteria from the
Enterococcus groups are present in signiﬁcantly higher
numbers in the SDD compared to both SC and SOD
regimens. The other groups of bacteria show some
variations but these are not signiﬁcant between both
other regimens.
The hypothesis that SDD is unequivocally beneﬁcial
by only reducing Enterobacteriaceae while leaving the
colonic microbiota unaffected has to be rejected.
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